$AMPE News

Last published 2y ago

2y agoAMPEAmpio Pharmaceuticals Received Audit Opinion with Going Concern ExplanationPR NewswireAmpio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company" or "Ampio") today announced that, as previously disclosed in its Annual Report on...
2y agoAMPEAmpio Announces Voluntary Delisting and SEC DeregistrationPR NewswireAmpio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company" or "Ampio") today announced that its Board of Directors determined to voluntarily...
2y agoAMPEAmpio Provides Update on Results from Pre-IND Enabling StudiesPR NewswireAmpio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company" or "Ampio"), a pre-revenue stage biopharmaceutical company focused on development of ...
2y agoAMPEAmpio Provides Litigation Update - Reports Settlement in Principle of Certain Pending Legal ActionsPR NewswireAmpio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company" or "Ampio"), a pre-revenue stage biopharmaceutical company focused on development of ...
3y agoAMPEAmpio Pharmaceuticals to Present at the Emerging Growth ConferencePR NewswireAmpio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company), a pre-revenue stage biopharmaceutical company focused on development of a potential ...
3y agoAMPEAmpio Selects Ascendia Pharmaceuticals, Inc. to Provide CDMO Services to Support Clinical Development of OA-201PR NewswireENGLEWOOD, Colo., Oct. 5, 2023 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE) (the "Company), a pre-revenue stage biopharmaceutical company focused on development of a potential treatment for osteoarthritis
3y agoAMPEAmpio Pharmaceuticals to Present at the Emerging Growth ConferencePR NewswireENGLEWOOD, Colo., Sept. 26, 2023 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE) (the "Company") a pre-revenue stage biopharmaceutical Company focused on development of a potential treatment for
3y agoAMPEAmpio Pharmaceuticals Announces Reverse Stock SplitPR NewswireENGLEWOOD, Colo., Aug. 31, 2023 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE) (the "Company") today announced that its Board of Directors has approved a 20-to-1 reverse stock split of the Company's
3y agoAMPEAmpio Pharmaceuticals Announces Series D Preferred Stock Dividend to its Holders of Common StockPR NewswireENGLEWOOD, Colo., May 26, 2023 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE) (the "Company") today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly
3y agoAMPEAMPIO PHARMACEUTICALS ISSUES LETTER TO STOCKHOLDERSPR NewswireENGLEWOOD, Colo., April 18, 2023 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE) (the "Company") today released the following letter to stockholders from its Chairman, Kevin Buchi and Chief Executive
3y agoAMPEAMPIO PHARMACEUTICALS ISSUES LETTER TO STOCKHOLDERSPR NewswireENGLEWOOD, Colo., Jan. 17, 2023 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE) (the "Company") today released the following letter to stockholders from its Chairman, Kevin Buchi and Chief Executive
3y agoAMPEAmpio Pharmaceuticals Regains Compliance with NYSE American Continued Listing StandardsPR NewswireENGLEWOOD, Colo., Dec. 27, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE) (the "Company") today announced that it has received notification from The NYSE American LLC ("NYSE American")
4y agoAMPEAmpio Pharmaceuticals Issues Letter to StockholdersPR NewswireDelisting Notice Underlines Urgency to Approve Proposal to Authorize a Reverse Stock-Split ENGLEWOOD, Colo., Oct. 4, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE), today released the following letter to stockholders from its Chairman, Ke
4y agoAMPEAmpio Pharmaceuticals Announces NYSE American Has Commenced Delisting ProceedingsPR NewswireENGLEWOOD, Colo., Oct. 4, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE) (the "Company") received written notification from NYSE American LLC ("NYSE American" or the "Exchange") stating that the staff of NYSE Regulation has determined to co
4y agoAMPESecurities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Ampio To Contact Him Directly To Discuss Their OptionsACCESS NewswireNEW YORK, NY / ACCESSWIRE / September 29, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ampio Pharmaceuticals, Inc. ("Ampio" or the "Company") (NYSE:AMPE) and reminds investors of the Octob
4y agoAMPESecurities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Ampio To Contact Him Directly To Discuss Their OptionsACCESS NewswireNEW YORK, NY / ACCESSWIRE / September 27, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ampio Pharmaceuticals, Inc. ("Ampio" or the "Company") (NYSEAMERICAN:AMPE) and reminds investors of
4y agoAMPESecurities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Ampio To Contact Him Directly To Discuss Their OptionsACCESS NewswireNEW YORK, NY / ACCESSWIRE / September 22, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ampio Pharmaceuticals, Inc. ("Ampio" or the "Company") (NYSE:AMPE) and reminds investors of the Octob
4y agoAMPESecurities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Ampio To Contact Him Directly To Discuss Their OptionsACCESS NewswireNEW YORK, NY / ACCESSWIRE / September 19, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ampio Pharmaceuticals, Inc. ("Ampio" or the "Company") (NYSEAMERICAN:AMPE) and reminds investors of
4y agoAMPESecurities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Ampio To Contact Him Directly To Discuss Their OptionsACCESS NewswireNEW YORK, NY / ACCESSWIRE / September 15, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ampio Pharmaceuticals, Inc. ("Ampio" or the "Company") (NYSE:AMPE) and reminds investors of the Octob
4y agoAMPESecurities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Ampio To Contact Him Directly To Discuss Their OptionsACCESS NewswireNEW YORK, NY / ACCESSWIRE / September 13, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ampio Pharmaceuticals, Inc. ("Ampio" or the "Company") (NYSEAMERICAN:AMPE) and reminds investors of
4y agoAMPEMoore Kuehn, PLLC Encourages Investors of Ampio Pharmaceuticals, Inc. to Contact Law FirmGlobeNewswireNEW YORK, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Ampio Pharmaceuticals, Inc. (NYSE:AMPE) breached their fiduciary duties to sharehol
4y agoAMPESecurities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Ampio To Contact Him Directly To Discuss Their OptionsACCESS NewswireNEW YORK, NY / ACCESSWIRE / September 8, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ampio Pharmaceuticals, Inc. ("Ampio" or the "Company") (NYSE:AMPE) and reminds investors of the Octobe
4y agoAMPESecurities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Ampio To Contact Him Directly To Discuss Their OptionsACCESS NewswireNEW YORK, NY / ACCESSWIRE / September 5, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ampio Pharmaceuticals, Inc. ("Ampio" or the "Company") (NYSE:AMPE) and reminds investors of the Octobe
4y agoAMPESecurities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Ampio To Contact Him Directly To Discuss Their OptionsACCESS NewswireNEW YORK, NY / ACCESSWIRE / September 4, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ampio Pharmaceuticals, Inc. ("Ampio" or the "Company") (NYSE:AMPE) and reminds investors of the Octobe
4y agoAMPESecurities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Ampio To Contact Him Directly To Discuss Their OptionsACCESS NewswireNEW YORK, NY / ACCESSWIRE / September 2, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ampio Pharmaceuticals, Inc. ("Ampio" or the "Company") (NYSE:AMPE) and reminds investors of the Octobe
4y agoAMPESecurities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Ampio To Contact Him Directly To Discuss Their OptionsACCESS NewswireNEW YORK, NY / ACCESSWIRE / August 30, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ampio Pharmaceuticals, Inc. ("Ampio" or the "Company") (NYSE:AMPE) and reminds investors of the October
4y agoAMPESecurities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Ampio To Contact Him Directly To Discuss Their OptionsACCESS NewswireNEW YORK, NY / ACCESSWIRE / August 25, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ampio Pharmaceuticals, Inc. ("Ampio" or the "Company") (NYSE:AMPE) and reminds investors of the October
4y agoAMPESecurities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Ampio To Contact Him Directly To Discuss Their OptionsACCESS NewswireNEW YORK, NY / ACCESSWIRE / August 22, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ampio Pharmaceuticals, Inc. ("Ampio" or the "Company") (NYSE:AMPE) and reminds investors of the October
4y agoAMPESecurities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Ampio To Contact Him Directly To Discuss Their OptionsACCESS NewswireNEW YORK, NY / ACCESSWIRE / August 21, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ampio Pharmaceuticals, Inc. ("Ampio" or the "Company") (NYSE:AMPE) and reminds investors of the October
4y agoAMPESecurities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Ampio To Contact Him Directly To Discuss Their OptionsACCESS NewswireNEW YORK, NY / ACCESSWIRE / August 19, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ampio Pharmaceuticals, Inc. ("Ampio" or the "Company") (NYSE:AMPE) and reminds investors of the October
4y agoAMPESecurities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Ampio To Contact Him Directly To Discuss Their OptionsACCESS NewswireNEW YORK, August 18, 2022 / Accesswire / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ampio Pharmaceuticals, Inc. ("Ampio" or the "Company") (NYSE:AMPE) and reminds investors of the October 17, 2
4y agoAMPEAmpio Pharmaceuticals Issues Letter to StockholdersPR NewswireENGLEWOOD, Colo., Aug. 3, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE), today released the following letter to stockholders from its Chairman, Kevin Buchi and Chief Executive Officer, Mike Martino.
4y agoAMPEAmpio Pharmaceuticals' CEO Mike Martino Issues Letter to StockholdersPR NewswireENGLEWOOD, Colo., June 2, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for the treatment of pain resulting from osteoarthritis in the knee and potential
4y agoAMPEAmpio Pharmaceuticals Reports First-Quarter Financial ResultsPR NewswireENGLEWOOD, Colo., May 16, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for the treatment of pain resulting from osteoarthritis in the knee and potentia
4y agoAMPEAmpio Independent Committee to Conduct InvestigationPR NewswireENGLEWOOD, Colo., May 16, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE) ("Ampio" or the "Company") today announced that an independent special committee of the Ampio Board of Directors (the "Committee"), with the assistance of independent
4y agoAMPEAmpio Pharmaceuticals, Inc. to Hold Conference CallPR NewswireENGLEWOOD, Colo., April 27, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for the treatment of pain resulting from osteoarthritis in the knee and potent
4y agoAMPEAMPIO PROVIDES REGULATORY UPDATEPR NewswireENGLEWOOD, Colo., April 20, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for the treatment of pain resulting from osteoarthritis in the knee and potent
4y agoAMPEAmpio Pharmaceuticals Reports Fourth-Quarter and Full-Year 2021 Financial Results and Operational HighlightsPR NewswireCash and Cash Equivalents of $34 Million Expected to Fund Current Operations into 2H 2023 Company to host Conference Call Tuesday, March 29, 2022, at 4:30pm EDT ENGLEWOOD, Colo., March 29, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE)
4y agoAMC AMPE HYMC IQ+1Thinking about buying stock in Mullen Automotive, Ampio Pharmaceuticals, AMC Entertainment, Hycroft Mining, or IQIYI?PR NewswireNEW YORK, March 24, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MULN, AMPE, AMC, HYMC, and IQ. T
4y agoAMPEAmpio Pharmaceuticals, Inc. to Hold Fourth Quarter 2021 Earnings and Business Update CallPR NewswireENGLEWOOD, Colo., March 23, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for the treatment of pain resulting from osteoarthritis, announced that the C
4y agoAMPEAmpio Pharmaceuticals to Participate at the 34th Annual Roth ConferencePR NewswireENGLEWOOD, Colo., March 9, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for the treatment of pain resulting from osteoarthritis, will attend the 34t
4y agoAMPEAmpio Pharmaceuticals, Inc. Releases Positive Phase 3 Data Analysis for Ampion™ Targeting Severe Osteoarthritis of the Knee (OAK)PR NewswireENGLEWOOD, Colo., March 2, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for common inflammatory conditions, today announced positive data from the mod
4y agoAMPEAmpio Pharmaceuticals, Inc. to Host a Conference Call and WebinarPR NewswireENGLEWOOD, Colo., March 2, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for common inflammatory conditions, announced that the Company will be hosting
4y agoAMPEAmpio Expands Board of Directors with Addition of Elizabeth Varki JobesPR NewswireENGLEWOOD, Colo., Feb. 10, 2022 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE:AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for prevalent inflammatory conditions, today announced the appointment of Elizabeth
4y agoAMPEAmpio Pharmaceuticals Presents Corporate Overview at H.C. Wainwright Bioconnect ConferencePR NewswireENGLEWOOD, Colo., Jan. 6, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced that it will present at
4y agoAMPEAmpio Pharmaceuticals' CEO Mike Martino Issues Letter to StockholdersPR NewswireENGLEWOOD, Colo., Dec. 16, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE:AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today released the following letter to stockh
4y agoAMPEAMPIO PHARMACEUTICALS ANNOUNCES PRICING OF $22.5 MILLION REGISTERED DIRECT OFFERINGPR NewswireENGLEWOOD, Colo., Dec. 13, 2021 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced that it has entered into
4y agoAMPEAmpio Pharmaceuticals, Inc. - Appeal, ReversedUS Patent Trial and Appeal Board
4y agoAMPEAmpio Pharmaceuticals to Host Business Update Call with Chairman and CEO Mike Martino on Wednesday, Dec. 1PR NewswireENGLEWOOD, Colo., Nov. 29, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE:AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced it will host a business updat
4y agoAMPEAmpio Pharmaceuticals Announces Shareholder / Business Update Call with its CEO & Chairman, Michael MartinoPR NewswireENGLEWOOD, Colo., Nov. 23, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE:AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced it will host a conference call